Pfizer Inc. and BioNTEch SE have announced promising findings from a Phase 1/2 trial of their mRNA flu/COVID vaccine. The trial, which involved adults aged 18 to 64, compared the vaccine candidates with a licensed influenza vaccine and the companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
According to a joint statement, the results revealed significant immune responses to influenza A, influenza B, and SARS-CoV-2 strains among participants who received the lead formulations of the combined vaccine. These encouraging findings offer promising prospects for the development of combination vaccines that can effectively combat respiratory diseases.
Professor Ugur Sahin, Co-Founder and CEO of BioNTech, expressed optimism about the potential of combination vaccines as a routine preventive measure against respiratory illnesses, particularly for populations at higher risk of severe illness. In light of these positive outcomes, Pfizer and BioNTech plan to move forward with a Phase 3 trial in the near future.
Despite the encouraging news, there was minimal impact on the stock market. Pre-market trading saw Pfizer's stock remain stable, while BioNTech experienced a modest 1.3% increase in its stock value. With further advancements in their clinical trials, Pfizer and BioNTech are inching closer to delivering a breakthrough mRNA flu/COVID vaccine that could have a profound impact on public health worldwide.